230 results on '"Thomas Réjean"'
Search Results
2. T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
- Author
-
Côté Pierre, Thomas Réjean, Routy Jean-Pierre, Boulet Salix, Tsoukas Christos M, Kamya Philomena, Boulassel Mohamed-Rachid, Lessard Bernard, Kaul Rupert, Ostrowski Mario, Kovacs Colin, Tremblay Cecile L, and Bernard Nicole F
- Subjects
HIV infection ,Elite controllers ,activation markers ,CD4 count change ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Elite controllers (EC) are a rare subset of HIV infected individuals who control viral load below 50 copies/ml of plasma without treatment. Methods Thirty four EC were studied. The slope of CD4 count change was available for 25 of these subjects. We assessed immune activation by measuring the percent of CD38+HLA-DR+CD8+ T cells in the EC group and comparing it with that in 24 treatment-naïve HIV disease progressors and 13 HIV uninfected healthy controls. Results Compared to HIV uninfected subjects, EC had higher percentages of CD38+HLA-DR+CD8+ T cells (p < 0.001) that was lower than that observed in progressors (p < 0.01). Fifteen of 25 EC had a slope of CD4 count change that was not significantly different from 0 while 3 had a positive and 7 a negative CD4 count slope. Immune activation did not distinguish EC subsets with stable/increasing versus declining CD4 counts. Conclusions Elevated immune activation in ECs is not associated with a faster rate of CD4 decline
- Published
- 2011
- Full Text
- View/download PDF
3. Population‐level effectiveness of pre‐exposure prophylaxis for HIV prevention among men who have sex with men in Montréal (Canada): a modelling study of surveillance and survey data
- Author
-
Doyle, Carla M., Milwid, Rachael M., Cox, Joseph, Xia, Yiqing, Lambert, Gilles, Tremblay, Cécile, Otis, Joanne, Boily, Marie‐Claude, Baril, Jean‐Guy, Thomas, Réjean, Blais, Alexandre Dumont, Trottier, Benoit, Grace, Daniel, Moore, David M., Mishra, Sharmistha, and Maheu‐Giroux, Mathieu
- Subjects
Medical care -- Utilization ,MSM (Men who have sex with men) -- Health aspects ,HIV infection -- Prevention ,Company distribution practices ,Health - Abstract
: Introduction: HIV pre‐exposure prophylaxis (PrEP) has been recommended and partly subsidized in Québec, Canada, since 2013. We evaluated the population‐level impact of PrEP on HIV transmission among men who have sex with men (MSM) in Montréal, Québec's largest city, over 2013–2021. Methods: We used an agent‐based mathematical model of sexual HIV transmission to estimate the fraction of HIV acquisitions averted by PrEP compared to a counterfactual scenario without PrEP. The model was calibrated to local MSM survey, surveillance, and cohort data and accounted for COVID‐19 pandemic impacts on sexual activity, HIV prevention, and care. PrEP was modelled from 2013 onwards, assuming 86% individual‐level effectiveness. The PrEP eligibility criteria were: any anal sex unprotected by condoms (past 6 months) and either multiple partnerships (past 6 months) or multiple uses of post‐exposure prophylaxis (lifetime). To assess potential optimization strategies, we modelled hypothetical scenarios prioritizing PrEP to MSM with high sexual activity (≥11 anal sex partners annually) or aged ⩽45 years, increasing coverage to levels achieved in Vancouver, Canada (where PrEP is free‐of‐charge), and improving retention. Results: Over 2013–2021, the estimated annual HIV incidence decreased from 0.4 (90% credible interval [CrI]: 0.3–0.6) to 0.2 (90% CrI: 0.1–0.2) per 100 person‐years. PrEP coverage among HIV‐negative MSM remained low until 2015 ( Conclusions: PrEP reduced population‐level HIV transmission among Montréal MSM. However, our study suggests missed prevention opportunities and adds support for public policies that reduce PrEP barriers, financial or otherwise, to MSM at risk of HIV acquisition., INTRODUCTION After over 20 years under study [1–3] and 10 years of availability [4], oral pre‐exposure prophylaxis (PrEP) has proven highly efficacious for preventing HIV acquisition across transmission routes. Rigorous [...]
- Published
- 2023
- Full Text
- View/download PDF
4. Effect of autogenic training on quality of life and symptoms in people living with HIV: A mixed method randomized controlled trial
- Author
-
Ramirez Garcia, Maria Pilar, Leclerc-Loiselle, Jérôme, Côté, José, Brouillette, Marie-Josée, and Thomas, Réjean
- Published
- 2023
- Full Text
- View/download PDF
5. A longitudinal view of successful aging with HIV: role of resilience and environmental factors
- Author
-
Mayo, Nancy E., Brouillette, Marie-Josée, Nadeau, Lyne, Dendukuri, Nandini, Harris, Marianne, Smaill, Fiona, Smith, Graham, Thomas, Réjean, and Fellows, Lesley K.
- Published
- 2022
- Full Text
- View/download PDF
6. Past dynamics of HIV transmission among men who have sex with men in Montréal, Canada: a mathematical modeling study
- Author
-
Milwid, Rachael M., Xia, Yiqing, Doyle, Carla M., Cox, Joseph, Lambert, Gilles, Thomas, Réjean, Mishra, Sharmistha, Grace, Daniel, Lachowsky, Nathan J., Hart, Trevor A., Boily, Marie-Claude, and Maheu-Giroux, Mathieu
- Published
- 2022
- Full Text
- View/download PDF
7. The process of learning the autogenic training relaxation technique and its benefits on the wellness of people living with HIV
- Author
-
Ramirez Garcia, Maria Pilar, Leclerc-Loiselle, Jérôme, Côté, José, Brouillette, Marie-Josée, and Thomas, Réjean
- Published
- 2022
- Full Text
- View/download PDF
8. Phylogenetic Network Analyses Reveal the Influence of Transmission Clustering on the Spread of HIV Drug Resistance in Quebec from 2002 to 2022.
- Author
-
Brenner, Bluma G., Ibanescu, Ruxandra-Ilinca, Oliveira, Maureen, Margaillan, Guillaume, Lebouché, Bertrand, Thomas, Réjean, Baril, Jean Guy, Lorgeoux, René-Pierre, Roger, Michel, and Routy, Jean-Pierre
- Subjects
NON-nucleoside reverse transcriptase inhibitors ,ANTI-HIV agents ,DRUG resistance ,ANTIRETROVIRAL agents ,PRE-exposure prophylaxis - Abstract
Background: HIV drug resistance (HIV-DR) may jeopardize the benefit of antiretroviral therapy (ART) in treatment and prevention. This study utilized viral phylogenetics to resolve the influence of transmission networks on sustaining the spread of HIV-DR in Quebec spanning 2002 to 2022. Methods: Time trends in acquired (ADR) and transmitted drug resistance (TDR) were delineated in treatment-experienced (n = 3500) and ART-naïve persons (n = 6011) with subtype B infections. Similarly, non-B-subtype HIV-DR networks were assessed pre- (n = 1577) and post-ART experience (n = 488). Risks of acquisition of resistance-associated mutations (RAMs) were related to clustering using 1, 2–5, vs. 6+ members per cluster as categorical variables. Results: Despite steady declines in treatment failure and ADR since 2007, rates of TDR among newly infected, ART-naive persons remained at 14% spanning the 2007–2011, 2012–2016, and 2017–2022 periods. Notably, half of new infections among men having sex with men and heterosexual groups were linked in large, clustered networks having a median of 35 (14–73 IQR) and 16 (9–26 IQR) members per cluster, respectively. Cluster membership and size were implicated in forward transmission of non-nucleoside reverse transcriptase inhibitor NNRTI RAMs (9%) and thymidine analogue mutations (TAMs) (5%). In contrast, transmission of M184V, K65R, and integrase inhibitors (1–2%) remained rare. Levels of TDR reflected viral replicative fitness. The median baseline viremia in ART-naïve groups having no RAMs, NNRTI RAMs, TAMs, and M184VI were 46.088, 38,447, 20,330, and 6811 copies/mL, respectively (p < 0.0001). Conclusion: Phylogenetics emphasize the need to prioritize ART and pre-exposure prophylaxis strategies to avert the expansion of transmission cascades of HIV-DR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Chemsex practices and pre-exposure prophylaxis (PrEP) trajectories among individuals consulting for PrEP at a large sexual health clinic in Montréal, Canada (2013-2020)
- Author
-
Flores Anato, Jorge Luis, Panagiotoglou, Dimitra, Greenwald, Zoë R., Trottier, Claire, Vaziri, Maliheh, Thomas, Réjean, and Maheu-Giroux, Mathieu
- Published
- 2021
- Full Text
- View/download PDF
10. Relationships between cognition, function, and quality of life among HIV+ Canadian men
- Author
-
investigators from the Positive Brain He Now Study, Mayo, Nancy E., Brouillette, Marie-Josée, Scott, Susan C., Harris, Marianne, Smaill, Fiona, Smith, Graham, Thomas, Réjean, and Fellows, Lesley K.
- Published
- 2020
11. IL-32 Drives the Differentiation of Cardiotropic CD4+ T Cells Carrying HIV DNA in People With HIV.
- Author
-
Ramani, Hardik, Gosselin, Annie, Bunet, Rémi, Jenabian, Mohammad-Ali, Sylla, Mohamed, Pagliuzza, Amélie, Chartrand-Lefebvre, Carl, Routy, Jean-Pierre, Goulet, Jean-Philippe, Thomas, Réjean, Trottier, Benoit, Martel-Laferrière, Valérie, Fortin, Claude, Chomont, Nicolas, Fromentin, Rémi, Landay, Alan L, Durand, Madeleine, Ancuta, Petronela, El-Far, Mohamed, and Tremblay, Cecile
- Subjects
T cells ,HIV-positive persons ,INTERLEUKIN-32 ,PROTEIN-tyrosine kinases ,IMMUNOLOGIC memory ,VIRAL tropism - Abstract
Interleukin 32 (IL-32) is a potent multi-isoform proinflammatory cytokine, which is upregulated in people with HIV (PWH) and is associated with cardiovascular disease (CVD) risk. However, the impact of IL-32 isoforms on CD4 T-cell cardiotropism, a mechanism potentially contributing to heart inflammation, remains unknown. Here we show that IL-32 isoforms β and γ induce the generation of CCR4
+ CXCR3+ double positive (DP) memory CD4 T-cell subpopulation expressing the tyrosine kinase receptor c-Met, a phenotype associated with heart-homing of T cells. Our ex vivo studies on PWH show that the frequency of DP CD4 T cells is significantly higher in individuals with, compared to individuals without, subclinical atherosclerosis and that DP cells from antiretroviral-naive and treated individuals are highly enriched with HIV DNA. Together, these data demonstrate that IL-32 isoforms have the potential to induce heart-homing of HIV-infected CD4 T cells, which may further aggravate heart inflammation and CVD in PWH. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
12. Cross-sectional comparison of age- and gender-related comorbidities in people living with HIV in Canada
- Author
-
Brunetta, Jason M., Baril, Jean-Guy, de Wet, Joseph J., Fraser, Chris, Rubin, Gary, Thomas, Réjean, Loemba, Hugues, Logue, Ken, Silverman, Michael, Palmart, Jean, Jiang, Haiyan, Lorgeoux, René-Pierre, Tossonian, Harout, Kim, Connie J., and Wong, Alexander
- Published
- 2022
- Full Text
- View/download PDF
13. Conceptions of sexual health by gay men living with HIV in serodifferent couples in Montreal, Canada: results from a qualitative analysis.
- Author
-
Avallone, Francesco, Engler, Kim, Cox, Joseph, Hickson, Ford, Lessard, David, Bourdon, Jeanne, Thomas, Réjean, and Lebouché, Bertrand
- Abstract
Background: Gay, bisexual, and other men (GBM) who have sex with men living with HIV in serodifferent couples (one partner living with HIV, the other HIV-negative) may encounter unique sexual health challenges. This study aimed to explore their definition of sexual health that could improve service provision. Methods: We interviewed 10 gay-identified men living with HIV from 2017 to 2019 as part of CTNPT013, a study on the sexual health of HIV serodifferent GBM couples conducted at two HIV-specialised clinics in Montreal, Canada. Participants partook in semi-structured interviews on the meaning of sexual health. We performed a content analysis of interview transcripts, coding them according to the 10 dimensions of Robinson's Sexual Health Model. Results: Mean age of interviewees was 35.4 years (s.d.,10.2; range, 20–53). Every dimension of Robinson's model was spontaneously evoked, except for body image and spirituality. All men indicated intimacy/relationships (e.g. sexual agreements) and sexual health care/safer sex (e.g. HIV management, risk behaviours) as relevant aspects of sexual health. Other dimensions included: positive sexuality (n = 7), such as pleasure and enjoyment during sex; talking about sex (n = 5), which mainly concerned HIV disclosure; sexual functioning (n = 4); challenges to sexual health (n = 3), including substance abuse; and culture/sexual identity (n = 3). Two participants (n = 2) cited masturbation/fantasy. Conclusions: This study emphasises the multi-faceted nature of sexual health for gay men with HIV in serodifferent couples and the pivotal roles of relationships, HIV, risk management (e.g. via health care, knowledge), and positive sexual experiences. These dimensions could be considered in sexual health promotion interventions targeting this population. Sexual health is a complex, multi-dimensional concept; however, much research on the topic is focused on sexually transmitted infections and risk reduction. Given their status as a key population for sexual health promotion, we interviewed 10 gay men living with HIV about the meaning of sexual health. While all mentioned sexual health care and safer sex (e.g. HIV management), most also addressed intimacy and relationships and well as positive sexuality as key components of sexual health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Recurrence of Human Papillomavirus External Genital Wart Infection Among High-Risk Adults in Montréal, Canada
- Author
-
Thomas, Réjean, Steben, Marc, Greenwald, Zoë, Stutz, Melissa, Rodier, Caroline, DeAngelis, Fern, and Rampakakis, Emmanouil
- Published
- 2017
15. Pre-exposure prophylaxis uptake among men who have sex with men who used non-occupational post-exposure prophylaxis: a longitudinal analysis of attendees at a large sexual health clinic in Montréal (Canada)
- Author
-
Xia, Yiqing, Greenwald, Zoë R., Milwid, Rachael M., Claire, Trottier, Boissonnault, Michel, Gaul, Neil, Charest, Louise, Landry, Gabrielle, Navid, Zahedi N., Szabo, Jason, Thomas, Réjean, and Maheu-Giroux, Mathieu
- Published
- 2020
- Full Text
- View/download PDF
16. Effectiveness of a Web-Based Intervention to Support Medication Adherence Among People Living With HIV: Web-Based Randomized Controlled Trial
- Author
-
Côté, José, Rouleau, Geneviève, Ramirez-Garcia, Maria Pilar, Auger, Patricia, Thomas, Réjean, and Leblanc, Judith
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
BackgroundTaking antiretroviral therapy (ART) is part of the daily life of people living with HIV. Different electronic health (eHealth) initiatives adjunctive to usual care have been proposed to support optimal medication adherence. A web-based intervention called HIV Treatment, Virtual Nursing Assistance, and Education or VIH-TAVIE (from its French version Virus de l’immunodéficience humaine-Traitement assistance virtuelle infirmière et enseignement) was developed to empower people living with HIV to manage their ART and symptoms optimally. ObjectiveWe aimed to evaluate the effectiveness of VIH-TAVIE in a web-based randomized controlled trial (RCT). MethodsThis RCT was entirely web-based, including recruitment, consent granting, questionnaire completion, and intervention exposure (consultation with VIH-TAVIE [experimental group] or websites [control group]). To be eligible for the study, people living with HIV had to be 18 years or older, be on ART for at least 6 months, have internet access, and have internet literacy. Participants were randomly assigned to either the experimental group (n=45) or control group (n=43). The primary outcome was ART adherence. The secondary outcomes included self-efficacy regarding medication intake, symptom-related discomfort, skills and strategies, and social support. All outcomes were measured with a self-administered web-based questionnaire at the following three time points: baseline and 3 and 6 months later. A generalized linear mixed model was built to assess the evolution of ART adherence over time in both groups. ResultsThe sample included 88 participants, and of these, 73 (83%) were men. The median age of the participants was 42 years. Participants had been diagnosed with HIV a median of 7 years earlier (IQR 3-17) and had been on ART for a median of 5 years (IQR 2-12). The proportion of treatment-adherent participants at baseline was high in both groups (34/41, 83% in the experimental group and 30/39, 77% in the control group). Participants also reported high treatment adherence, high self-efficacy, and high skills; perceived good social support; and experienced low discomfort from symptoms. Analyses revealed no intergroup difference regarding ART adherence (OR 1.9, 95% CI 0.6-6.4). ConclusionsThis study highlights the challenges and lessons learned from conducting an entirely web-based RCT among people living with HIV. The challenges were related to the engagement of people living with HIV on the following three levels: starting the web-based study (recruitment), completing the web-based intervention (engagement), and continuing the study (retention). The results contribute to the existing body of knowledge regarding how to conduct web-based evaluation studies of eHealth interventions aimed at developing and strengthening personal skills and abilities. Trial RegistrationClinicalTrials.gov NCT01510340; https://clinicaltrials.gov/ct2/show/NCT01510340
- Published
- 2020
- Full Text
- View/download PDF
17. Pre-exposure Prophylaxis Uptake Among Men Who Have Sex With Men Who Used nPEP: A Longitudinal Analysis of Attendees at a Large Sexual Health Clinic in Montréal (Canada)
- Author
-
Xia, Yiqing, Greenwald, Zoë R., Milwid, Rachael M., Trottier, Claire, Boissonnault, Michel, Gaul, Neil, Charest, Louise, Landry, Gabrielle, N. Zahedi, Navid, Szabo, Jason, Thomas, Réjean, and Maheu-Giroux, Mathieu
- Published
- 2020
- Full Text
- View/download PDF
18. Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
- Author
-
Sangaré, Mohamed N’dongo, Baril, Jean-Guy, de Pokomandy, Alexandra, Laprise, Claudie, Deshaies, Catherine, Klein, Marina, Thomas, Réjean, Tremblay, Cécile, Roger, Michel, Pexos, Costa, Greenwald, Zoe, Machouf, Nima, Durand, Madeleine, Hardy, Isabelle, Dakouo, Mamadou, Laporte, Louise, and Trottier, Helen
- Published
- 2020
- Full Text
- View/download PDF
19. Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV.
- Author
-
Giguère, Katia, Chartrand‐Lefebvre, Carl, Baril, Jean‐Guy, Conway, Brian, El‐Far, Mohamed, Falutz, Julian, Harris, Marianne, Jenabian, Mohammad‐Ali, Leipsic, Jonathon, Loutfy, Mona, Mansour, Samer, MacPherson, Paul, Margolese, Shari, McMillan, Jacqueline M., Monteith, Ken, Murray, Melanie C. M., Pick, Neora, Thomas, Réjean, Trottier, Benoît, and Trottier, Sylvie
- Subjects
HIV infection complications ,HIV-positive persons ,CARDIOVASCULAR diseases risk factors ,RESEARCH ,RISK assessment ,AGING ,LONGITUDINAL method - Abstract
Objectives: Our objective was to report the baseline characteristics of participants in the Canadian HIV and Aging Cohort Study (CHACS) and present amendments to the initial protocol. Methods: CHACS is a multi‐centred prospective cohort study that was initially set from 2011 to 2016 and will now continue recruitment until 2024. Four additional years of follow‐up have been added, and additional outcomes and covariates will be prospectively collected. Frailty will be assessed using a modified version of the Fried's frailty phenotype. The four interrelated aspects of gender—gender roles, gender identity, gender relationships, and institutionalized gender—will be measured using the GENESIS‐PRAXY questionnaire. Diet will be assessed using a validated, web‐based, self‐administered food frequency questionnaire. Results: A total of 1049 participants (77% people living with HIV) were recruited between September 2011 and September 2019. Median age at baseline was 54 years (interquartile range 50–61). Most participants were male (84%) and white (83%). Compared with participants without HIV, those with HIV were more likely to be male; to report lower education levels and incomes; to be more sedentary; to use tobacco, recreational, and prescription drugs; to report a personal history of cardiovascular diseases; and to be frail. Conclusions: The new assessments added to the CHACS protocol will allow for an even more detailed portrait of the pathways leading to accentuated aging for people living with HIV. Participants in the CHACS cohort display important differences in socio‐economic and cardiovascular risk factors according to HIV serostatus. These imbalances must be taken into account for all further inferential analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Impact of Loneliness on Brain Health and Quality of Life Among Adults Living With HIV in Canada
- Author
-
Harris, Marianne, Brouillette, Marie-Josée, Scott, Susan C., Smaill, Fiona, Smith, Graham, Thomas, Réjean, Fellows, Lesley K., and Mayo, Nancy E.
- Published
- 2020
- Full Text
- View/download PDF
21. Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs
- Author
-
Zaidan, Sarah M., Leyre, Louise, Bunet, Rémi, Larouche-Anctil, Etienne, Turcotte, Isabelle, Sylla, Mohamed, Chamberland, Annie, Chartrand-Lefebvre, Carl, Ancuta, Petronela, Routy, Jean-Pierre, Baril, Jean-Guy, Trottier, Benoit, MacPherson, Paul, Trottier, Sylvie, Harris, Marianne, Walmsley, Sharon, Conway, Brian, Wong, Alexander, Thomas, Réjean, Kaplan, Robert C., Landay, Alan L., Durand, Madeleine, Chomont, Nicolas, Tremblay, Cécile L., and El-Far, Mohamed
- Published
- 2019
- Full Text
- View/download PDF
22. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
- Author
-
Brenner, Bluma G, Oliveira, Maureen, Ibanescu, Ruxandra-Ilinca, Routy, Jean-Pierre, and Thomas, Réjean
- Subjects
VIRAL mutation ,MUPIROCIN ,LAMIVUDINE ,EFAVIRENZ ,RAMS ,HIV - Abstract
Objectives The NNRTI doravirine has been recently approved for the first-line treatment of HIV-infected patients, eliciting favourable responses against viruses bearing the K103N, Y181C and G190A mutations. This study used in vitro drug selections to elaborate the breadth of doravirine responses against viruses bearing NNRTI and NRTI resistance-associated mutations (RAMs). Methods WT clinical isolates (n = 6) and viruses harbouring common NRTI and NNRTI RAMs (n = 6) were serially passaged in escalating concentrations of doravirine, doravirine/islatravir, doravirine/lamivudine and rilpivirine over 24 weeks. Genotypic analysis ascertained the appearance and accumulation of NNRTI RAMs. Phenotypic drug susceptibility assays assessed resistance conferred by acquired NNRTI RAMs. Results For WT viruses, doravirine pressure led to the appearance of V108I or V106A/I/M RAMs after 8 weeks, conferring low-level (∼2-fold) resistance. After 24 weeks, the accumulation of three to six secondary RAMs, including F227L, M230L, L234I and/or Y318, resulted in high-level (>100-fold) resistance to doravirine. Notably, viruses with these doravirine RAMs remained susceptible to rilpivirine and efavirenz. This contrasted with rilpivirine where acquisition of E138K, L100I and/or K101E resulted in >50-fold cross-resistance to all NNRTIs. Doravirine selection of viruses bearing common NRTI and NNRTI RAMs showed delayed acquisition of RAMs compared with WT virus. Pairing doravirine with islatravir or lamivudine attenuated the development of NNRTI RAMs. Conclusions Doravirine showed favourable resistance profiles against viruses harbouring NRTI and NNRTI RAMs. The high barrier to resistance to doravirine coupled with the long intracellular half-life of islatravir may provide the opportunity for long-acting treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection
- Author
-
Jenabian, Mohammad-Ali, El-Far, Mohamed, Vyboh, Kishanda, Kema, Ido, Costiniuk, Cecilia T., Thomas, Rejean, Baril, Jean-Guy, LeBlanc, Roger, Kanagaratham, Cynthia, Radzioch, Danuta, Allam, Ossama, Ahmad, Ali, Lebouché, Bertrand, Tremblay, Cécile, Ancuta, Petronela, and Routy, Jean-Pierre
- Published
- 2015
24. Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV
- Author
-
Nguyen, Vinh-Kim, Greenwald, Zoë R., Trottier, Helen, Cadieux, Martha, Goyette, Alexandre, Beauchemin, Mariève, Charest, Louise, Longpré, Danièle, Lavoie, Stéphane, Tossa, Hermione Gbego, and Thomas, Réjean
- Published
- 2018
- Full Text
- View/download PDF
25. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis
- Author
-
Tan, Darrell H. S., Hull, Mark W., Yoong, Deborah, Tremblay, Cécile, O’Byrne, Patrick, Thomas, Réjean, Kille, Julie, Baril, Jean-Guy, Cox, Joseph, Giguere, Pierre, Harris, Marianne, Hughes, Christine, MacPherson, Paul, O’Donnell, Shannon, Reimer, Joss, Singh, Ameeta, Barrett, Lisa, Bogoch, Isaac, Jollimore, Jody, Lambert, Gilles, Lebouche, Bertrand, Metz, Gila, Rogers, Tim, and Shafran, Stephen
- Published
- 2017
- Full Text
- View/download PDF
26. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
- Author
-
Sangaré, Mohamed N'dongo, Baril, Jean-Guy, Pokomandy, Alexandra de, Klein, Marina, Thomas, Réjean, Tremblay, Cécile, Pexos, Costa, Durand, Madeleine, Chawla, Seerat, Laporte, Louise, and Trottier, Helen
- Subjects
HIV infections ,HIV integrase inhibitors ,PROTEASE inhibitors ,CONFIDENCE intervals ,VIRAL load ,REVERSE transcriptase inhibitors ,ANTIRETROVIRAL agents ,PROTEOLYTIC enzymes ,HIGHLY active antiretroviral therapy ,TREATMENT effectiveness ,COMPARATIVE studies ,CD4 lymphocyte count ,IMMUNITY ,DESCRIPTIVE statistics ,RESEARCH funding ,T cells ,LONGITUDINAL method - Abstract
Background The impact of different therapeutic classes of drugs in antiretroviral therapy (ART) regimens on the CD4/CD8 ratio is not well documented in people treated for HIV. The objective of this study was to analyze the long-term effect of exposure to integrase strand transfer inhibitor (INSTI) on CD4/CD8 ratio compared with nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) among ART-treated persons with HIV (PWH). Methods Data from the Quebec HIV Cohort collected from 31 August 2017 were used. Our analysis included all patients in the cohort who received a first or subsequent ART regimen composed of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a third active drug of a different class (NNRTI, PI, or INSTI) for at least 16 weeks. Marginal structural Cox models were constructed to estimate the effect of different therapeutic classes on the CD4/CD8 ratio outcome. Results Among the 3907 eligible patients, 972 (24.9%), 1996 (51.1%), and 939 (24.0%) were exposed to an ART regimen whose third active agent was an NNRTI, PI, or INSTI, respectively. The total follow-up time was 13 640.24 person-years. The weighted hazard ratio for the association between the third active class and CD4/CD8 ratio ≥1 was.56 (95% confidence interval [CI]:.48–.65) for patients exposed to NNRTI + 2 NRTIs and.41 (95% CI:.35–.47) for those exposed to PI + 2 NRTIs, compared with those exposed INSTI + 2 NRTIs. Conclusions For people treated for HIV, INSTI-based ART appears to be associated with a higher CD4/CD8 ratio than NNRTI and PI-based ART. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Association Between the Development of Subclinical Cardiovascular Disease and Human Immunodeficiency Virus (HIV) Reservoir Markers in People With HIV on Suppressive Antiretroviral Therapy.
- Author
-
Turcotte, Isabelle, El-Far, Mohamed, Sadouni, Manel, Chartrand-Lefebvre, Carl, Filali-Mouhim, Ali, Fromentin, Rémi, Chamberland, Annie, Jenabian, Mohammad-Ali, Baril, Jean-Guy, Trottier, Benoit, Thomas, Réjean, Tremblay, Cécile L, Durand, Madeleine, Chomont, Nicolas, and Study, the Canadian HIV and Aging Cohort
- Subjects
CARDIOVASCULAR disease diagnosis ,HIV-positive persons ,ANTIRETROVIRAL agents ,MANN Whitney U Test ,CD4 lymphocyte count ,DESCRIPTIVE statistics ,RESEARCH funding ,LOGISTIC regression analysis ,DATA analysis software ,HIV - Abstract
We report that people with human immunodeficiency virus (HIV) diagnosed with coronary artery atherosclerotic plaques display higher levels of HIV DNA compared with those without atherosclerotic plaques. In a multivariable prediction model that included 27 traditional and HIV-related risk factors, measures of HIV DNA were among the most important predictors of atherosclerotic plaque formation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Differential Impact of IL-32 Isoforms on the Functions of Coronary Artery Endothelial Cells: A Potential Link with Arterial Stiffness and Atherosclerosis.
- Author
-
Bunet, Rémi, Roy-Cardinal, Marie-Hélène, Ramani, Hardik, Cleret-Buhot, Aurélie, Durand, Madeleine, Chartrand-Lefebvre, Carl, Routy, Jean-Pierre, Thomas, Réjean, Trottier, Benoît, Ancuta, Petronela, Hanna, David B., Landay, Alan L., Cloutier, Guy, Tremblay, Cécile L., and El-Far, Mohamed
- Subjects
ARTERIAL diseases ,CORONARY arteries ,ENDOTHELIAL cells ,ENDOTHELIUM diseases ,INTERLEUKIN-32 ,ATHEROSCLEROSIS - Abstract
Chronic inflammation is associated with higher risk of cardiovascular disease (CVD) in people living with HIV (PLWH). We have previously shown that interleukin-32 (IL-32), a multi-isoform proinflammatory cytokine, is chronically upregulated in PLWH and is linked with CVD. However, the mechanistic roles of the different IL-32 isoforms in CVD are yet to be identified. In this study, we aimed to investigate the potential impact of IL-32 isoforms on coronary artery endothelial cells (CAEC), whose dysfunction represents a major factor for atherosclerosis. Our results demonstrated that the predominantly expressed IL-32 isoforms (IL-32β and IL-32γ) have a selective impact on the production of the proinflammatory cytokine IL-6 by CAEC. Furthermore, these two isoforms induced endothelial cell dysfunction by upregulating the expression of the adhesion molecules ICAM-I and VCAM-I and the chemoattractants CCL-2, CXCL-8 and CXCL-1. IL-32-mediated expression of these chemokines was sufficient to drive monocyte transmigration in vitro. Finally, we demonstrate that IL-32 expression in both PLWH and controls correlates with the carotid artery stiffness, measured by the cumulated lateral translation. These results suggest a role for IL-32-mediated endothelial cell dysfunction in dysregulation of the blood vessel wall and that IL-32 may represent a therapeutic target to prevent CVD in PLWH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection
- Author
-
Quebec Primary HIV Infection Study Group, Brenner, Bluma G., Roger, Michel, Routy, Jean-Pierre, Moisi, Daniela, Ntemgwa, Michel, Matte, Claudine, Baril, Jean-Guy, Thomas, Réjean, Rouleau, Danielle, Bruneau, Julie, Leblanc, Roger, Legault, Mario, Tremblay, Cecile, Charest, Hugues, and Wainberg, Mark A.
- Published
- 2007
- Full Text
- View/download PDF
30. The Role of Phylogenetics in Unravelling Patterns of HIV Transmission towards Epidemic Control: The Quebec Experience (2002–2020)
- Author
-
Brenner, Bluma G., Ibanescu, Ruxandra-Ilinca, Osman, Nathan, Cuadra-Foy, Ernesto, Oliveira, Maureen, Chaillon, Antoine, Stephens, David, Hardy, Isabelle, Routy, Jean-Pierre, Thomas, Réjean, Baril, Jean-Guy, Leblanc, Roger, Tremblay, Cecile, Roger, Michel, and Group, The Montreal Primary HIV Infection (PHI) Cohort Study Group The Montreal Primary HIV Infection (PHI) Cohort Study
- Subjects
Adult ,Male ,HIV-1 transmission ,men having sex with men ,HIV Infections ,non-B subtypes ,Biology ,migration ,Microbiology ,Article ,Young Adult ,Phylogenetics ,Virology ,80 and over ,2.2 Factors relating to the physical environment ,Humans ,Men having sex with men ,Aetiology ,Homosexuality, Male ,Hiv transmission ,Epidemics ,Epidemic control ,Phylogeny ,Aged ,Aged, 80 and over ,Transmission (medicine) ,Prevention ,Quebec ,Homosexuality ,Middle Aged ,Treatment as prevention ,QR1-502 ,phylogenetics ,Viral phylodynamics ,Infectious Diseases ,Good Health and Well Being ,HIV-TRACE ,treatment-as-prevention ,HIV-1 ,HIV/AIDS ,Female ,Viral spread ,Infection ,Demography - Abstract
Phylogenetics has been advanced as a structural framework to infer evolving trends in the regional spread of HIV-1 and guide public health interventions. In Quebec, molecular network analyses tracked HIV transmission dynamics from 2002–2020 using MEGA10-Neighbour-joining, HIV-TRACE, and MicrobeTrace methodologies. Phylogenetics revealed three patterns of viral spread among Men having Sex with Men (MSM, n = 5024) and heterosexuals (HET, n = 1345) harbouring subtype B epidemics as well as B and non-B subtype epidemics (n = 1848) introduced through migration. Notably, half of new subtype B infections amongst MSM and HET segregating as solitary transmissions or small cluster networks (2–5 members) declined by 70% from 2006–2020, concomitant to advances in treatment-as-prevention. Nonetheless, subtype B epidemic control amongst MSM was thwarted by the ongoing genesis and expansion of super-spreader large cluster variants leading to micro-epidemics, averaging 49 members/cluster at the end of 2020. The growth of large clusters was related to forward transmission cascades of untreated early-stage infections, younger at-risk populations, more transmissible/replicative-competent strains, and changing demographics. Subtype B and non-B subtype infections introduced through recent migration now surpass the domestic epidemic amongst MSM. Phylodynamics can assist in predicting and responding to active, recurrent, and newly emergent large cluster networks, as well as the cryptic spread of HIV introduced through migration.
- Published
- 2021
- Full Text
- View/download PDF
31. The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection
- Author
-
Mehraj, Vikram, Jenabian, Mohammad-Ali, Ponte, Rosalie, Lebouché, Bertrand, Costiniuk, Cecilia, Thomas, Réjean, Baril, Jean-Guy, LeBlanc, Roger, Cox, Joseph, Tremblay, Cécile, and Routy, Jean-Pierre
- Published
- 2016
- Full Text
- View/download PDF
32. Monkeypox in Montréal: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak.
- Author
-
Harrison, Luke B., Bergeron, Geneviève, Cadieux, Geneviève, Charest, Hugues, Fafard, Judith, Levade, Inès, Blais, Antoine Cloutier, Huchet, Emmanuelle, Trottier, Benoît, Vlad, Dragos, Szabo, Jason, Thomas, Réjean, Poulin, Sébastien, Greenaway, Christina, Zaharatos, Gerasimos J., Oughton, Matthew, Chakravarti, Arpita, Pilarski, Robert, Bui-Nguyen, Andrew, and Benomar, Khadija
- Subjects
MONKEYPOX ,ZOONOSES ,PUBLIC health ,VIRUS diseases ,TULAREMIA - Abstract
A global outbreak of monkeypox occurred beginning in mid-2022 outside endemic areas. The authors of this article use epidemiologic and laboratory surveillance data and a phylogenomic analysis to describe the monkeypox outbreak in Montréal—the first large outbreak in North America—and place it in a global context. Visual Abstract. Monkeypox in Montréal.: A global outbreak of monkeypox occurred beginning in mid-2022 outside endemic areas. The authors of this article use epidemiologic and laboratory surveillance data and a phylogenomic analysis to describe the monkeypox outbreak in Montréal—the first large outbreak in North America—and place it in a global context. Background: Monkeypox, a viral zoonotic disease, is causing a global outbreak outside of endemic areas. Objective: To characterize the outbreak of monkeypox in Montréal, the first large outbreak in North America. Design: Epidemiologic and laboratory surveillance data and a phylogenomic analysis were used to describe and place the outbreak in a global context. Setting: Montréal, Canada. Patients: Probable or confirmed cases of monkeypox. Measurements: Epidemiologic, clinical, and demographic data were aggregated. Whole-genome sequencing and phylogenetic analysis were performed for a set of outbreak sequences. The public health response and its evolution are described. Results: Up to 18 October 2022, a total of 402 cases of monkeypox were reported mostly among men who have sex with men (MSM), most of which were suspected to be acquired through sexual contact. All monkeypox genomes nested within the B.1 lineage. Montréal Public Health worked closely with the affected communities to control the outbreak, becoming the first jurisdiction to offer 1 dose of the Modified Vaccinia Ankara-Bavarian Nordic vaccine as preexposure prophylaxis (PrEP) to those at risk in early June 2022. Two peaks of cases were seen in early June and July (43 and 44 cases per week, respectively) followed by a decline toward near resolution of the outbreak in October. Reasons for the biphasic peak are not fully elucidated but may represent the tempo of vaccination and/or several factors related to transmission dynamics and case ascertainment. Limitations: Clinical data are self-reported. Limited divergence among sequences limited genomic epidemiologic conclusions. Conclusion: A large outbreak of monkeypox occurred in Montréal, primarily among MSM. Successful control of the outbreak rested on early and sustained engagement with the affected communities and rapid offer of PrEP vaccination to at-risk persons. Primary Funding Source: None. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028) †.
- Author
-
Mboumba Bouassa, Ralph-Sydney, Needham, Judy, Nohynek, Dana, Singer, Joel, Lee, Terry, Bobeuf, Florian, Samarani, Suzanne, Del Balso, Lina, Paisible, Natalie, Vertzagias, Claude, Sebastiani, Giada, Margolese, Shari, Mandarino, Enrico, Klein, Marina, Lebouché, Bertrand, Cox, Joseph, Brouillette, Marie-Josée, Routy, Jean-Pierre, Szabo, Jason, and Thomas, Réjean
- Subjects
CANNABINOIDS ,HIV-positive persons ,TETRAHYDROCANNABINOL ,CLINICAL trials ,CANNABIDIOL ,PHLEBOTOMY - Abstract
Background: With anti-inflammatory properties, cannabinoids may be a potential strategy to reduce immune activation in people living with HIV (PLWH) but more information on their safety and tolerability is needed. Methods: We conducted an open-label interventional pilot study at the McGill University Health Centre in Montreal, Canada. PLWH were randomized to oral Δ9-tetrahydrocannabinol (THC): cannabidiol (CBD) combination (THC 2.5 mg/CBD 2.5 mg) or CBD-only capsules (CBD 200 mg). Individuals titrated doses as tolerated to a maximum daily dose THC 15 mg/CBD 15 mg or 800 mg CBD, respectively, for 12 weeks. The primary outcome was the percentage of participants without any significant toxicity based on the WHO toxicity scale (Grades 0–2 scores). Results: Out of ten individuals, eight completed the study. Two from the CBD-only arm were withdrawn for safety concerns: phlebotomy aggravating pre-existing anemia and severe hepatitis on 800 mg CBD with newly discovered pancreatic adenocarcinoma, respectively. Seven did not have any significant toxicity. Cannabinoids did not alter hematology/biochemistry profiles. CD4 count, CD4/CD8 ratio, and HIV suppression remained stable. Most adverse effects were mild-moderate. Conclusions: In PLWH, cannabinoids seem generally safe and well-tolerated, though larger studies are needed. Screening for occult liver pathology should be performed and hepatic enzymes monitored, especially with high CBD doses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Chemsex and incidence of sexually transmitted infections among Canadian pre-exposure prophylaxis (PrEP) users in the l'Actuel PrEP Cohort (2013-2020).
- Author
-
Flores Anato, Jorge Luis, Panagiotoglou, Dimitra, Greenwald, Zoë R., Blanchette, Maxime, Trottier, Claire, Vaziri, Maliheh, Charest, Louise, Szabo, Jason, Thomas, Réjean, and Maheu-Giroux, Mathieu
- Abstract
Objectives: Use of illicit substances during sex (chemsex) may increase transmission of HIV and other STIs. Pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV transmission, providing an important prevention tool for those who practise chemsex. However, it does not prevent acquisition of other STIs. We aim to examine the impact of chemsex on STI incidence among gay, bisexual and other men who have sex with men (gbMSM), and transgender women using PrEP in Montréal, Canada.Methods: We linked baseline sociodemographic and behavioural data with follow-up STI testing from 2013 to 2020 among PrEP users in the l'Actuel PrEP Cohort (Canada). Focusing on the 24 months following PrEP initiation, we estimated the effect of chemsex reported at baseline on cumulative incidence of gonorrhoea and chlamydia using Kaplan-Meier curves and survival analyses. We investigated the role of polysubstance use and effect modification by sociodemographic factors.Results: There were 2086 clients (2079 cisgender gbMSM, 3 transgender gbMSM, 4 transgender women) who initiated PrEP, contributing 1477 years of follow-up. There were no incident HIV infections among clients on PrEP. Controlling for sociodemographic confounders, clients reporting chemsex at baseline had a 32% higher hazard of gonorrhoea/chlamydia diagnosis (adjusted HR=1.32; 95% CI: 1.10 to 1.57), equivalent to a risk increase of 8.9 percentage points (95% CI: 8.5 to 9.4) at 12 months. The effect was greater for clients who reported polysubstance use (adjusted HR=1.51; 95% CI: 1.21 to 1.89). The strength of the effect of chemsex on STI incidence varied by age, education and income.Conclusion: Among PrEP users, chemsex at baseline was linked to increased incidence of gonorrhoea and chlamydia. This effect was stronger for people reporting multiple chemsex substances. The high STI incidence among gbMSM who report chemsex highlights the importance of PrEP for this population and the need for integrated services that address the complexities of sexualised substance use. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
35. Human Immunodeficiency Virus (HIV)-Specific Effector CD8 T Cell Activity in Patients with Primary HIV Infection
- Author
-
Alter, Galit, Merchant, Alefia, Tsoukas, Christos M., Rouleau, Danielle, LeBlanc, Roger P., Côté, Pierre, Baril, Jean-Guy, Thomas, Réjean, Nguyen, Vinh-Kim, Sékaly, Rafik-Pierre, Routy, Jean-Pierre, and Bernard, Nicole F.
- Published
- 2002
36. Socio-economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015
- Author
-
Mehraj, Vikram, Cox, Joseph, Lebouché, Bertrand, Costiniuk, Cecilia, Cao, Wei, Li, Taisheng, Ponte, Rosalie, Thomas, Réjean, Szabo, Jason, Baril, Jean?Guy, Trottier, Benoit, Côté, Pierre, Leblanc, Roger, Bruneau, Julie, Tremblay, Cécile, Routy, Jean?Pierre, Charest, L., Milne, C., Lavoie, S., Friedman, J., Duchastel, M., Villielm, F., Asselin, F., Boissonnault, M., Maziade, P.J., Milne, M., Lessard, B., Charron, M.A., Dufresne, S., Turgeon, M.E., Vezina, S., Huchet, E., Kerba, J.P., Poliquin, M., Poulin, S., Rochette, P., Junod, P., Longpré, D., Pilarski, R., Sasseville, E., Labrecque, L., Fortin, C., Hal?Gagne, V., Munoz, M., Deligne, B., Martel?Laferriere, V., Goyer, M.E, Gilmore, N., Potter, M., Klein, M., Teltscher, M., Pokomandy, A., Haraoui, L.P., Rivet, Nathalie, Nguyen, Tuyen, Bernard, Nicole, Dupuy, Franck, Cohen, Eric A., Ancuta, Petronela, Roger, Michel, Wainberg, Mark A., and Brenner, Bluma G.
- Subjects
Medical care, Cost of -- Analysis ,Antiviral agents -- Dosage and administration ,HIV patients -- Care and treatment ,HIV infection -- Care and treatment ,Health - Abstract
: Introduction: Guidelines regarding antiretroviral therapy (ART) initiation in HIV infection have varied over time, with the 2015 World Health Organization recommendation suggesting ART initiation at the time of diagnosis regardless of CD4 T‐cell counts. Herein, we investigated the influence of socio‐demographic and clinical factors in addition to time trends on early ART initiation among participants of the Montreal Primary HIV Infection Study. Methods: The Montreal Primary HIV Infection Study is a prospective cohort established in three community medical centres (CMCs) and two university medical centres (UMCs). Recently diagnosed HIV‐infected adults were categorized as receiving early (vs. delayed) ART if ART was initiated within 180 days of the baseline visit. Associations between early ART initiation and socio‐demographic, socio‐economic and behavioural information were examined. Independent associations of factors linked with early ART initiation were determined using multivariable binary logistic regression analysis. Results: A total of 348 participants had a documented date of HIV acquisition of Conclusions: Early ART initiation during primary HIV infection was associated with diminished biological prognostic factors and calendar time mirroring evolution of treatment guidelines. In addition, socio‐economic factors such as having a paid employment, contribute to early ART initiation in the context of universal access to care in Canada., Introduction Human immunodeficiency virus (HIV) affects over 36.7 million people worldwide. Nearly, half of those infected with HIV remain untreated, increasing their risks for acquired immune deficiency syndrome (AIDS), onward [...]
- Published
- 2018
- Full Text
- View/download PDF
37. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance
- Author
-
Hardy, Isabelle, Brenner, Bluma, Quashie, Peter, Thomas, Réjean, Petropoulos, Christos, Huang, Wei, Moisi, Daniela, Wainberg, Mark A., and Roger, Michel
- Published
- 2015
- Full Text
- View/download PDF
38. Trends in Use of Combination Antiretroviral Therapy and Treatment Response from 2000 to 2016 in the Canadian Observational Cohort (CANOC): A Longitudinal Cohort Study.
- Author
-
McClean, Alison R., Trigg, Jason, Cardinal, Claudette, Loutfy, Mona, Cooper, Curtis, Kroch, Abigail, Shokoohi, Mostafa, Machouf, Nimâ, Thomas, Réjean, Klein, Marina B., Kelly, Deborah V., Wong, Alexander, Sanche, Stephen, Montaner, Julio S. G., and Hogg, Robert S.
- Subjects
HIV infections ,TENOFOVIR ,IMMUNE system ,HEALING ,HIGHLY active antiretroviral therapy ,TREATMENT effectiveness ,CD4 lymphocyte count ,DRUG utilization ,LONGITUDINAL method ,EMTRICITABINE - Abstract
Copyright of Canadian Journal of Hospital Pharmacy / Journal Canadien de la Pharmacie Hospitalière is the property of Canadian Society of Hospital Pharmacists and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
39. Tobacco smoking and HIV-related immunologic and virologic response among individuals of the Canadian HIV Observational Cohort (CANOC).
- Author
-
McClean, Alison R., Kooij, Katherine W., Trigg, Jason, Ye, Monica, Sereda, Paul, McLinden, Taylor, Bacani, Nicanor, Aran, Niloufar, Thomas, Réjean, Wong, Alexander, Klein, Marina B., Hull, Mark, Cooper, Curtis, Salters, Kate, and Hogg, Robert S.
- Subjects
HIV infections ,IMMUNOLOGY ,CONFIDENCE intervals ,CONVALESCENCE ,ANTIRETROVIRAL agents ,TREATMENT effectiveness ,RESEARCH funding ,CD4 lymphocyte count ,SMOKING ,VIROLOGY ,ODDS ratio - Abstract
We assessed the relationship between tobacco smoking and immunologic and virologic response among people living with HIV (PLWH) initiating combination antiretroviral therapy (cART) in the Canadian HIV Observational Cohort (CANOC). Positive immunologic and virologic response, respectively, were defined as ≥50 cells/mm
3 CD4 count increase (CD4+) and viral suppression ≤50 copies/mL (VL+) within 6 months of cART initiation. Using multinomial regression, we examined the relationship between smoking, immunologic, and virologic response category. Model A adjusted for birth sex, baseline age, enrolling province, and era of cohort entry; models B and C further adjusted for neighbourhood level material deprivation and history of injection drug use (IDU), respectively. Among 4267 individuals (32.7%) with smoking status data, concordant positive (CD4+/VL+) response was achieved by 64.2% never, 66.9% former, and 59.4% current smokers. In the unadjusted analysis, current smoking was significantly associated with concordant negative response (odds ratio [OR] 1.85, 95% confidence interval [CI] 1.40–2.45). Similarly, models A and B showed an increased odds of concordant negative response in current smokers (adjusted OR [aOR] 1.78, 95% CI 1.32–2.39 and 1.74, 95% CI 1.29–2.34, respectively). The association between current smoking and concordant negative response was no longer significant in model C (aOR 1.18, 95%CI 0.85–1.65). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
40. Factors partitioning physical frailty in people aging with HIV: A classification and regression tree approach.
- Author
-
Inceer, Mehmet, Brouillette, Marie‐J., Fellows, Lesley K., Morais, José A., Harris, Marianne, Smaill, Fiona, Smith, Graham, Thomas, Réjean, and Mayo, Nancy E.
- Subjects
HIV-positive persons ,LIFESTYLES ,FRAIL elderly ,CONFIDENCE intervals ,HYPOTHYROIDISM ,CANNABIS (Genus) ,CROSS-sectional method ,REGRESSION analysis ,AGING ,ODDS ratio ,COMORBIDITY ,PHENOTYPES ,TOBACCO - Abstract
Objective: To estimate the extent to which comorbidity and lifestyle factors were associated with physical frailty in middle‐aged and older Canadians living with HIV. Design: Cross‐sectional analysis of 856 participants from the Canadian Positive Brain Health Now cohort. Methods: The frailty indicator phenotype was adapted from Fried's criteria using self‐report items. Univariate logistic regression and classification and regression tree (CaRT) models were used to identify the most relevant independent contributors to frailty. Results: In all, 100 men (14.0%) and 26 women (19.7%) were identified as frail (≥ 3/5 criteria) for an overall prevalence of 15.2%. Nine comorbidities showed an influential association with frailty. The most influential comorbidities were hypothyroidism [odds ratio (OR) = 2.55, 95% confidence interval (CI): 1.29–5.03] and arthritis (OR = 2.54, 95% CI: 1.58–4.09). Additionally, tobacco (OR = 1.79, 95% CI: 1.05–3.04) showed an association. Any level of alcohol consumption showed a protective effect for frailty. The CaRT model showed nine pathways that led to frailty. Arthritis was the most discriminatory variable followed by alcohol, hypothyroidism, tobacco, cancer, cannabis, liver disease, kidney disease, osteoporosis, lung disease and peripheral vascular disease. The prevalence of physical frailty for people with arthritis was 27.4%; with additional cancer or tobacco and alcohol the prevalence rates were 47.1% and 46.1%, respectively. The protective effect of alcohol consumption evident in the univariate model appeared again in the CaRT model, but this effect varied. Cognitive frailty (19.5% overall) and emotional frailty (37.9% overall) were higher than the prevalence of physical frailty. Conclusions: Specific comorbidities and tobacco use were implicated in frailty, suggesting that it is comorbidities causing frailty. However, some frailty still appears to be HIV‐related. The higher prevalence of cognitive and emotional frailty highlights the fact that physical frailty should not be the only focus in HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy
- Author
-
Trottier, Benoit, Machouf, Nimâ, Thomas, Réjean, Gallant, Serge, Longpré, Danièle, Vézina, Sylvie, Boissonnault, Michel, Lavoie, Stéphane, Legault, Danielle, Dion, Harold, and Nguyen, Vinh Kim
- Published
- 2012
42. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
- Author
-
Routy, Jean-Pierre, Machouf, Nimâ, Edwardes, Michael D, Brenner, Bluma G, Thomas, Réjean, Trottier, Benoit, Rouleau, Danielle, Tremblay, Cécile L, Côté, Pierre, Baril, Jean-Guy, Remis, Robert S, Sékaly, Rafick P, and Wainberg, Mark A
- Published
- 2004
43. Characteristics of new HIV diagnoses over 1995–2019: A clinic-based study in Montréal, Canada.
- Author
-
Giguère, Katia, Vaziri, Maliheh, Olivier, Clément, Charest, Louise, Szabo, Jason, Thomas, Réjean, and Maheu-Giroux, Mathieu
- Subjects
HIV prevention ,CLINICS ,DRUG abuse ,DIAGNOSIS ,HIV infections ,HUMAN sexuality ,HIV ,HIV-positive persons - Abstract
Background: Characterization of populations at risk of acquiring HIV is required to inform the public health response to HIV. To identify potential changing needs in HIV prevention and care cascade, we aim to describe how the demographic profiles and exposure categories of newly diagnosed HIV positive individuals attending a large sexual health clinic in Montréal (Canada) evolved since the beginning of the antiretroviral therapy era in the mid-1990s. Methods: Using diagnosis data from participants of the Clinique médicale l'Actuel cohort of HIV-positive patients, we examined the distribution of exposure categories (sexual orientation, sexual behaviours, injection drug use, being born in an HIV-endemic country) by gender and year of diagnosis. Time trends in mean age and in the proportion of patients with late (CD4 <350 cells/μL) or advanced stage (CD4 <200 cells/μL) of HIV infection at diagnosis were assessed through meta-regressions. Results: A total of 2,612 patients diagnosed with HIV between January 1
st , 1995 and December 31st , 2019 were included. Overall, mean age was 35 years (standard deviation: 10 years) and remained stable over time. The proportion of patients with advanced stage of HIV infection decreased from 16% in 1995 to 4% in 2019. Although men who have sex with men (MSM) consistently accounted for the highest proportion of new diagnoses (77%, 2,022/2,612 overall), their proportion decreased since 2013. There was also a concomitant decrease in the proportion of people who inject drugs, with none of the newly diagnosed participants reporting injection drug use since 2017, and an important increase in the proportion of patients born in an HIV-endemic country (24%, 7/29 in 2019), especially among women. Compared to patients from non-endemic countries, those from HIV-endemic countries were characterized by higher proportions of heterosexuals (88% vs 17%) and of women (52% vs 7%), and were twice likely to get diagnosed at an advanced stage of HIV infection (32% vs 15%). Conclusions: In absolute numbers, MSM continue to account for the largest exposure category. However, patients from HIV-endemic countries, who tend to be diagnosed at later stages of HIV infection, constitute an increasing proportion of newly diagnosed individuals. These persons could face distinct barriers to rapid diagnosis. Tailoring HIV testing strategies and other prevention interventions to the specific unmet prevention needs of these individuals is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
44. Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT).
- Author
-
Conway, Brian, Smyth, Dan, Thomas, Réjean, Wong, Alex, Sebastiani, Giada, Cooper, Curtis, Shah, Hemant, Kumar, Ritesh, Deutsch, Gretty, and Watson, Ted
- Published
- 2021
- Full Text
- View/download PDF
45. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
- Author
-
Brenner, Bluma G, Oliveira, Maureen, Ibanescu, Ruxandra-Ilinca, Routy, Jean-Pierre, and Thomas, Réjean
- Subjects
CELL culture ,SOMATIC mutation ,LAMIVUDINE ,CORD blood ,GENOTYPES ,DRUG resistance ,HIV infections ,ANTI-HIV agents ,PROTEINS ,PYRIDINE ,RESEARCH ,GENETIC mutation ,HETEROCYCLIC compounds ,REVERSE transcriptase inhibitors ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,ADENOSINES ,DRUG resistance in microorganisms ,HIV ,PHARMACODYNAMICS - Abstract
Background: The newer generation NNRTIs, including doravirine and rilpivirine, were designed to show high potency and overcome K103N, Y181C and G190A resistance.Objectives: To assess emergent resistance to doravirine and rilpivirine, alone and paired with lamivudine or islatravir through in vitro drug selections.Methods: Subtype B (n = 3), non-B subtype (n = 3), and pNL4.3 viral isolates were passaged in cord blood mononuclear cells with progressively increasing concentrations of drug(s). Genotypic analysis compared the acquisition and accumulation of drug resistance mutations at weeks 8 and 24 following drug pressure. Cell-based phenotypic assays assessed cross-resistance patterns to NNRTIs by acquired resistance mutations.Results: Doravirine pressure resulted in the acquisition of V108I (6/7) and V106A/I/M (5/7) mutations at weeks 8, followed by F227L (4/7), Y318F (4/7), M230L (2/7) or L234I (2/7) by weeks 24. In contrast, rilpivirine resulted in E138K (5/7) followed by L100I (3/7), K101E (1/7), or M230L (1/7). Doravirine resistance pathways retained susceptibility to rilpivirine, whereas rilpivirine resistance conferred intermediate resistance (12-152-fold) to doravirine. Dual selections with islatravir or lamivudine delayed and diminished emergent resistance to doravirine, resulting in V108I (9/15) with fewer or no other changes at weeks 24. There was a lesser delay in emergent resistance to rilpivirine when combined with islatravir or lamivudine. The M184V mutation did not arise in dual selections with islatravir or lamivudine.Conclusions: Doravirine showed a more robust resistance profile compared with other NNRTIs. The long intracellular half-life of islatravir and delayed acquisition of resistance in dual selections provide an opportunity for long-acting treatment options. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
46. Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis.
- Author
-
El-Far, Mohamed, Durand, Madeleine, Turcotte, Isabelle, Larouche-Anctil, Etienne, Sylla, Mohamed, Zaidan, Sarah, Chartrand-Lefebvre, Carl, Bunet, Rémi, Ramani, Hardik, Sadouni, Manel, Boldeanu, Irina, Chamberland, Annie, Lesage, Sylvie, Baril, Jean-Guy, Trottier, Benoit, Thomas, Réjean, Gonzalez, Emmanuel, Filali-Mouhim, Ali, Goulet, Jean-Philippe, and Martinson, Jeffrey A.
- Subjects
ATHEROSCLEROSIS ,HIV-positive persons ,SHORT-chain fatty acids ,FATTY acids ,DRUG target ,CORONARY disease - Abstract
Despite the success of antiretroviral therapy (ART), people living with HIV (PLWH) are still at higher risk for cardiovascular diseases (CVDs) that are mediated by chronic inflammation. Identification of novel inflammatory mediators with the inherent potential to be used as CVD biomarkers and also as therapeutic targets is critically needed for better risk stratification and disease management in PLWH. Here, we investigated the expression and potential role of the multi-isoform proinflammatory cytokine IL-32 in subclinical atherosclerosis in PLWH (n=49 with subclinical atherosclerosis and n=30 without) and HIV- controls (n=25 with subclinical atherosclerosis and n=24 without). While expression of all tested IL-32 isoforms (α, β, γ, D, ϵ, and θ) was significantly higher in peripheral blood from PLWH compared to HIV- controls, IL-32D and IL-32θ isoforms were further upregulated in HIV+ individuals with coronary artery atherosclerosis compared to their counterparts without. Upregulation of these two isoforms was associated with increased plasma levels of IL-18 and IL-1β and downregulation of the atheroprotective protein TRAIL, which together composed a unique atherosclerotic inflammatory signature specific for PLWH compared to HIV- controls. Logistic regression analysis demonstrated that modulation of these inflammatory variables was independent of age, smoking, and statin treatment. Furthermore, our in vitro functional data linked IL-32 to macrophage activation and production of IL-18 and downregulation of TRAIL, a mechanism previously shown to be associated with impaired cholesterol metabolism and atherosclerosis. Finally, increased expression of IL-32 isoforms in PLWH with subclinical atherosclerosis was associated with altered gut microbiome (increased pathogenic bacteria; Rothia and Eggerthella species) and lower abundance of the gut metabolite short-chain fatty acid (SCFA) caproic acid, measured in fecal samples from the study participants. Importantly, caproic acid diminished the production of IL-32, IL-18, and IL-1β in human PBMCs in response to bacterial LPS stimulation. In conclusion, our studies identified an HIV-specific atherosclerotic inflammatory signature including specific IL-32 isoforms, which is regulated by the SCFA caproic acid and that may lead to new potential therapies to prevent CVD in ART-treated PLWH. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. 'You're only there on the phone'? A qualitative exploration of community, affect and agential capacity in HIV self‐testing using a smartphone app.
- Author
-
Janssen, Ricky, Engel, Nora, Pant Pai, Nitika, Esmail, Aliasgar, Dheda, Keertan, Thomas, Réjean, and Krumeich, Anja
- Subjects
DIAGNOSIS of HIV infections ,MOBILE apps ,INTERVIEWING ,QUALITATIVE research ,TELEMEDICINE ,PATIENT self-monitoring - Abstract
Mobile health (mHealth) technologies for HIV care are developed to provide diagnostic support, health education, risk assessment and self‐monitoring. They aim to either improve or replace part of the therapeutic relationship. Part of the therapeutic relationship is affective, with the emergence of feelings and emotion, yet little research on mHealth for HIV care focuses on affect and HIV testing practices. Furthermore, most of the literature exploring affect and care relations with the introduction of mHealth is limited to the European and Australian context. This article explores affective dimensions of HIV self‐testing using a smartphone app strategy in Cape Town, South Africa and Montréal, Canada. This study is based on observation notes, 41 interviews and 1 focus group discussion with study participants and trained HIV healthcare providers from two quantitative studies evaluating the app‐based self‐test strategy. Our paper reveals how fear, apathy, judgement, frustration and comfort arise in testing encounters using the app and in previous testing experiences, as well as how this relates to care providers and test materials. Attending to affective aspects of this app‐based self‐testing practice makes visible certain affordances and limitations of the app within the therapeutic encounter and illustrates how mHealth can contribute to HIV care. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. A mixed-method randomized feasibility trial evaluating progressive muscle relaxation or autogenic training on depressive symptoms and quality of life in people living with human immunodeficiency virus (HIV) who have depressive symptoms.
- Author
-
Ramirez-Garcia, Maria Pilar, Leclerc-Loiselle, Jérôme, Gagnon, Marie-Pierre, Côté, José, Brouillette, Marie-Josée, and Thomas, Réjean
- Subjects
PILOT projects ,MUSCLE contraction ,CONFIDENCE intervals ,RESEARCH methodology ,TIME ,HYPNOTISM ,INTERVIEWING ,HEALTH outcome assessment ,RANDOMIZED controlled trials ,PATIENTS' attitudes ,MENTAL depression ,QUALITY of life ,DESCRIPTIVE statistics ,STATISTICAL sampling ,PSYCHOLOGY of HIV-positive persons - Abstract
Progressive muscle relaxation (PMR) and autogenic training (AT) are effective relaxation techniques to reduce depressive symptoms. However, no studies on their effectiveness have been conducted among people living with HIV and depressive symptoms. The primary aim of this pilot study was to assess the feasibility and acceptability of PMR and AT interventions among people living with HIV who have depressive symptoms. A secondary aim was to assess the potential effectiveness of these interventions on depressive symptoms and quality of life. This study was a three-arm pilot randomized control trial with mixed methods. Participants were randomized to PMR, AT, or a control group (CG), with four assessments (baseline, and at one, three, and six months). The PMR and AT interventions consisted of six 1 h sessions of individual training over 12 weeks, plus home practice. Recruitment, attrition, and completion rates were calculated. Depressive symptoms and quality of life were assessed at all times. Participants' perceptions of the interventions were collected in semi-structured interviews. Following the screening, 54/63 people met the inclusion criteria, and 42/54 were randomly allocated to the PMR group (n=14), AT group (n=14), and CG (n=14). Six participants (43%; 95% CI 18–71%) in the PMR group and 10 (71%; 95% CI 42–92%) in the AT group completed the intervention. Participants reported better emotion management and improvements in depressive symptoms and quality of life. The pilot study suggests that a randomized trial to test the effectiveness of these interventions is feasible. ClinicalTrials.gov NCT01901016 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy.
- Author
-
Lebouché, Bertrand, Yero, Alexis, Shi, Tao, Farnos, Omar, Singer, Joel, Kema, Ido, Costiniuk, Cecilia T., Thomas, Réjean, Brouillette, Marie-Josée, Engler, Kim, Routy, Jean-Pierre, and Jenabian, Mohammad-Ali
- Subjects
NIACIN ,ANTIRETROVIRAL agents ,NICOTINAMIDE ,TRYPTOPHAN ,HIV infections ,BLOOD lipids ,T helper cells ,CD4 antigen - Abstract
Background: Tryptophan (Trp) catabolism into immunosuppressive kynurenine (Kyn) is involved in immune dysregulation during HIV infection. Niacin (vitamin B3) could control the excess of tryptophan depletion and represents a potential strategy to improve immune functions and CD4 count recovery in immunological non-responder HIV-infected individuals on antiretroviral therapy (ART). Methods: In the CTN PT006 phase 2 pilot randomized trial, 20 adults on ART with CD4 ≤ 350 cells/µl, despite an undetectable viral load (VL) for at least 3 months, received 2000 mg of extended-release (ER)-niacin orally once daily for 24 weeks. Side effects, VL, CD4/CD8 counts, lipid profile, T-cell activation and senescence, Tregs and Th17 cell frequencies, Kyn/Trp ratio, and levels of IL-6, IP-10, sST2, I-FABP, and LBP were assessed following ER-niacin treatment. Results: Thirteen participants completed the study. Treatment was interrupted in 4 patients due to loss of follow-up or personal reasons and 3 patients were discontinued due to comorbidity risks. All participants maintained a VL < 40 copies/ml, while ER-niacin did not affect CD4 and CD8 cell counts. Plasma levels of triglycerides, total, and LDL cholesterol significantly decreased, following ER-niacin treatment. ER-niacin also diminished Kyn plasma levels and slightly decreased CD4 T-cell activation. However, no improvement in CD8 subsets, Kyn/Trp ratio, Th17/Treg balance, and plasma inflammatory markers was observed. Conclusions: Although ER-niacin combined with ART was well-tolerated among immune non-responders and decreased plasma lipids, it did not improve systemic inflammation, Kyn/Trp ratio, and CD4 cell recovery. Overall, ER-niacin was not effective to overcome chronic inflammation in PLWH. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
50. Pre-exposure Prophylaxis Uptake Among Men Who Have Sex With Men Who Used nPEP: A Longitudinal Analysis of Attendees at a Large Sexual Health Clinic in Montre'al (Canada).
- Author
-
Yiqing Xia, Greenwald, Zoë R., Milwid, Rachael M., Trottier, Claire, Boissonnault, Michel, Gaul, Neil, Charest, Louise, Landry, Gabrielle, Zahedi, Navid N., Szabo, Jason, Thomas, Réjean, and Maheu-Giroux, Mathieu
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.